ClinicalTrials.gg
Not yet recruitingNCT05592327Updated Oct 24, 2022

Citric Acid Passivation on Implant Abutments for the Prevention of Peri-implant Disease

An interventional study of Citric acid abutment in Peri-Implantitis, Implant Infection and Microbial Disease, sponsored by Universitat Internacional de Catalunya. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by Universitat Internacional de Catalunya · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya — 6 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Universitat Internacional de Catalunya.

Started
2022
with 1 other
No phase
7 of 15
4 open now
Registered
10th of 15
by date

Among the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, this one is one of 2 that started in 2022, is one of 7 with no phase, and was the 10th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

6 of the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, or all of them as a file.
02

Study summary

The use of dental implants is a predictable procedure to replace the missing tooth with high rates of success and survival. In addition, placing the abutment on the same day as the implant surgery is a safe and biologically sound procedure to minimize bone loss and peri-implant inflammation. Although citric acid antibacterial coating has never been tested in vivo, recent in vitro data support its clinical use due to its antibacterial effect at the abutment level.

This prospective randomized controlled clinical trial aims to evaluate the microbiological and inflammatory profile of implant abutments coated with citric acid.

Read the detailed description

The study population will consist on patients referred to the Department of Periodontology at Universitat Internacional de Catalunya for the replacement of missing teeth and who meet the following inclusion criteria will be included consecutively in the study.

5.3.1. Inclusion criteria

  • Patients with ≥18 years old.
  • Systemically healthy patients.
  • Patients with healthy periodontal status with a full mouth plaque index ≤ 20% (O'Leary, 1972) and full mouth bleeding index (Ainamo \& Bay, 1975) before implant surgery.
  • Need for at least one dental implant in maxillary and mandibular partially posterior edentulous healed sites.

5.3.2. Exclusion criteria

  • Patients with some special conditions that could interfere surgical oral procedures.
  • Patients with non-treated periodontal disease.
  • Patients with uncontrolled systemic disease that could impair wound healing (i.e. Diabetes Mellitus).
  • Pregnant women.
  • Patients allergic to any metallic component of the materials.
  • Need for bone or soft tissue reconstruction simultaneous to implant placement.
  • Lack of primary stability during implant placement (i.e., insertion torque \< 25 N, ISQ > 60)
  • Smokers ≥ 10 cigarettes per day.
  • Patients will be excluded from the study if they violate any of the criteria during the trial, as well as if they desire to withdraw the study or have any adverse reactions to the materials employed.

The primary outcome measure will be the reduction of biofilm formation at the test abutments compared with the control abutments at the 12 weeks 6 months, 1 year and 3 year of follow-up. Biofilm formation over abutments will be quantified with Ilumina sequencing analysis.

03

Conditions studied

  • Peri-Implantitis
  • Implant Infection
  • Microbial Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ≥18 years old.
  • Systemically healthy patients.
  • Patients with healthy periodontal status with a full mouth plaque index ≤ 20% (O'Leary, 1972) and full mouth bleeding index (Ainamo \& Bay, 1975) before implant surgery.
  • Need for at least one dental implant in maxillary and mandibular partially posterior edentulous healed sites.

Exclusion criteria

Exclusion Criteria:

  • Patients with some special conditions that could interfere surgical oral procedures.
  • Patients with non-treated periodontal disease.
  • Patients with uncontrolled systemic disease that could impair wound healing (i.e. Diabetes Mellitus).
  • Pregnant women.
  • Patients allergic to any metallic component of the materials.
  • Need for bone or soft tissue reconstruction simultaneous to implant placement.
  • Lack of primary stability during implant placement (i.e., insertion torque \< 25 N, ISQ > 60)
  • Smokers ≥ 10 cigarettes per day.
  • Patients will be excluded from the study if they violate any of the criteria during the trial, as well as those that desire to withdraw the study or have any adverse reactions to the materials employed.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Citric acid abutment

    Antimicrobial-coated abutments (citric acid) will be allocated to the test group. Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N

    Procedure: Citric acid abutment

  • Placebo comparator
    Control non coated abutment

    Non- coated abutments (citric acid) will be allocated to the control group. Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N

    Procedure: Citric acid abutment

Interventions

  • ProcedureCitric acid abutment

    The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.

06

What researchers measure

Primary outcomes

  1. Biofilm quantification

    The primary outcome measure will be the reduction of biofilm formation at the test abutments compared with the control abutments at the 12 weeks, 6 months, 1 year and 3 years. Biofilm formation over the retrieved abutments will be quantified by means of Illumina sequencing analysis

    Time frame: 12 weeks, 6 months, 1 and 3 years

Secondary outcomes

  1. Protein expression markers

    Quantification of protein expressions (IL-10 beta, IL-8 and TNF-beta) for the test and control abutments. This quantification will be performed at 12 weeks, 6 months, 1 and 3 years

    Time frame: 12 weeks, 6 months, 1 and 3 years

  2. Peri-implant disease incidence

    The incidence of peri-implant disease will be assessed at 1 and 3 years attending to the 2017 World Workshop Classification

    Time frame: 1 and 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2022; primary completion for Oct 2025, 35 months later.

Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 35 months is above that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2022
First posted
Oct 24, 2022
StartEst.
Nov 3, 2022
Primary completionEst.
Oct 2025
CompletionEst.
Dec 2025
Last update
Oct 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05592327
Collaborators
Klockner Implant System
Responsible party
Javi Vilarrasa (Doctor, Universitat Internacional de Catalunya) — Principal investigator
First posted
Oct 24, 2022
Start date
Nov 3, 2022 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 24, 2022

Study contacts

Javi Vilarrasa
Contact
jvilarrasa@uic.es
628553000
Javi Vilarrasa
principal investigator · Universitat Internacional de Catalunya

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion